Background: Idiopathic normal pressure hydrocephalus (iNPH) is a dementing condition featuring characteristic symptoms, ventriculomegaly, and normal or slightly elevated cerebrospinal fluid pressure. In Alzheimer’s disease (AD) patients, diffuse aggregates of amyloid-β (Aβ) and neurofibrillary hyperphosphorylated tau are detected in the neocortex of the brain, while similar accumulation of Aβ is also detected in iNPH. Recent genome-wide association studies have identified several novel risk loci for AD, potentially affecting Aβ-related cellular processes. Apart from the apolipoprotein E ɛ4 allele (APOE4), the risk effect of single loci is low, emphasizing the importance of the polygenic risk score approach when assessing the combined effects.
Objective: To study the effects of AD-associated individual and polygenic risk score of single nucleotide polymorphisms (SNPs) on the accumulation of Aβ in the brain samples of iNPH patients.
Methods: A sample set of frontal cortex biopsies from 188 iNPH patients were divided into two groups according to the Aβ pathology. After the genotyping of the AD-associated risk loci, polygenic risk score was calculated for each iNPH patient and subsequently analyzed in relation to Aβ deposition.
Results: Apart from the APOE4, none of the SNPs revealed a statistically significant effect on the accumulation of Aβ in iNPH. Also, the non-APOE4 polygenic risk score did not associate with Aβ deposition.
Conclusion: Novel AD-associated risk genes have no significant effect on Aβ accumulation in the brain of iNPH patients. However, APOE4 affects the Aβ deposition in the brain of iNPH and AD patients in a similar manner.
HakimS, AdamsRD (1965) The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure: Observations on cerebrospinal fluid hydrodynamics. J Neurol Sci2, 307–327.
LeinonenV, KoivistoAM, SavolainenS, RummukainenJ, TamminenJN, TillgrenT, VainikkaS, PyykköOT, MölsäJ, FraunbergM, PirttiläT, JääskeläinenJE, SoininenH, RinneJ, AlafuzoffI (2010) Amyloid and tau proteins in cortical brain biopsy and Alzheimer’s disease. Ann Neurol68, 446–453.
4.
LeinonenV, KoivistoAM, SavolainenS, RummukainenJ, SutelaA, VanninenR, JääskeläinenJE, SoininenH, AlafuzoffI (2012) Post-mortem findings in 10 patients with presumed normal pressure hydrocephalus and review of the literature. Neuropathol Appl Neurobiol38, 72–86.
5.
SelkoeDJ (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer’s disease. Trends Cell Biol8, 447–453.
6.
AsaiM, HattoriC, SzaboB, SasagawaN, MaruyamaK, TanumaS, IshiuraS (2003) Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun301, 231–235.
7.
VassarR, BennettBD, Babu-KhanS, KahnS, MendiazEA, DenisP, TeplowDB, RossS, AmaranteP, LoeloffR, LuoY, FisherS, FullerJ, EdensonS, LileJ, JarosinskiMA, BiereAL, CurranE, BurgessT, LouisJC, CollinsF, TreanorJ, RogersG, CitronM (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science286, 735–741.
8.
MüllerUC, ZhengH (2012) Physiological functions of APP family proteins. Cold Spring Harb Perspect Med2, a006288.
9.
PortenoyRK, BergerA, GrossE (1984) Familial occurrence of idiopathic normal pressure hydrocephalus. Arch Neurol41, 335–337.
10.
CusimanoMD, RewilakD, StussDT, Barrera-MartinezJC, SalehiF, FreedmanM (2011) normal-pressure hydrocephalus: Is there a genetic predisposition?Can J Neurol Sci38, 274–281.
11.
TakahashiY, KawanamiT, NagasawaH, IsekiC, HanyuH, KatoT (2011) Familial normal pressure hydrocephalus (NPH) with an autosomal-dominant inheritance: A novel subgroup of NPH. J Neurol Sci308, 149–151.
12.
BertramL, McQueenMB, MullinK, BlackerD, TanziRE (2007) Systematic meta-analyses of Alzheimer’s disease genetic association studies: The AlzGene database. Nat Genet39, 17–23.
13.
GuerreiroR, WojtasA, BrasJ, CarrasquilloM, RogaevaE, MajounieE, CruchagaC, SassiC, KauweJS, YounkinS, HazratiL, CollingeJ, PocockJ, LashleyT, WilliamsJ, LambertJC, AmouyelP, GoateA, RademakersR, MorganK, PowelJ, St George-HyslopP, SingletonA, HardyJ, Alzheimer Genetic Analysis Group (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med368, 117–127.
MartiskainenH, ViswanathanJ, NykänenNP, KurkiM, HelisalmiS, NatunenT, SarajärviT, KurkinenKM, PursiheimoJP, RauramaaT, AlafuzoffI, JääskeläinenJE, LeinonenV, SoininenH, HaapasaloA, HuttunenHJ, HiltunenM (2015) Transcriptomics and mechanistic elucidation of Alzheimer’s disease risk genes in the brain and in vitro models. Neurobiol Aging36, e15–e22.
16.
ChenY, DurakoglugilMS, XianX, HerzJ (2010) ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci U S A107, 12011–12016.
17.
LiuCC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer’s disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
18.
EvansDM, VisscherPM, WrayNR (2009) Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk. Hum Mol Genet18, 3525–3531.
19.
International Schizophrenia Consortium
, PurcellSM, WrayNR, StoneJL, VisscherPM, O’DonovanMC, SullivanPF, SklarP (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature460, 748–752.
20.
MartiskainenH, HelisalmiS, ViswanathanJ, KurkiM, HallA, HerukkaSK, SarajärviT, NatunenT, KurkinenKM, HuovinenJ, MäkinenP, LaitinenM, KoivistoAM, MattilaKM, LehtimäkiT, RemesAM, LeinonenV, HaapasaloA, SoininenH, HiltunenM (2015) Effects of Alzheimer’s disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: A polygenic risk score approach. J Alzheimers Dis43, 565–573.
21.
LambertJC, Grenier-BoleyB, HaroldD, ZelenikaD, ChourakiV, KamataniY, SleegersK, IkramMA, HiltunenM, ReitzC, MateoI, FeulnerT, BullidoM, GalimbertiD, ConcariL, AlvarezV, SimsR, GerrishA, ChapmanJ, Deniz-NaranjoC, SolfrizziV, SorbiS, ArosioB, SpallettaG, SicilianoG, EpelbaumJ, HannequinD, DartiguesJF, TzourioC, BerrC, SchrijversEM, RogersR, TostoG, PasquierF, BettensK, Van CauwenbergheC, FratiglioniL, GraffC, DelepineM, FerriR, ReynoldsCA, LannfeltL, IngelssonM, PrinceJA, ChillottiC, PilottoA, SeripaD, BolandA, MancusoM, BossuP, AnnoniG, NacmiasB, BoscoP, PanzaF, Sanchez-GarciaF, Del ZompoM, CotoE, OwenM, O’DonovanM, ValdiviesoF, CaffarraP, ScarpiniE, CombarrosO, BueeL, CampionD, SoininenH, BretelerM, RiemenschneiderM, Van BroeckhovenC, AlperovitchA, LathropM, TregouetDA, WilliamsJ, AmouyelP (2013) Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer’s disease. Mol Psychiatry18, 461–470.
LaiteräT, SarajärviT, HaapasaloA, PuliL, KauppinenT, MäkinenP, RauramaaT, TanilaH, JääskeläinenJE, AlafuzoffI, SoininenH, LeinonenV, HiltunenM (2014) Increased gamma-secretase activity in idiopathic normal pressure hydrocephalus patients with beta-amyloid pathology. PLoS One9, e93717.
26.
FarmeryMR, TjernbergLO, PursgloveSE, BergmanA, WinbladB, NaslundJ (2003) Partial purification and characterization of gamma-secretase from post-mortem human brain. J Biol Chem278, 24277–24284.
27.
SleegersK, BettensK, De RoeckA, Van CauwenbergheC, CuyversE, VerheijenJ, StruyfsH, Van DongenJ, VermeulenS, EngelborghsS, VandenbulckeM, VandenbergheR, De DeynPP, Van BroeckhovenC, Belneu Consortium (2015) A 22-single nucleotide polymorphism Alzheimer’s disease risk score correlates with family history, onset age, and cerebrospinal fluid Abeta42. Alzheimers Dement11, 1452–1460.
28.
PyykköOT, HelisalmiS, KoivistoAM, MölsäJA, RummukainenJ, NergO, AlafuzoffI, SavolainenS, SoininenH, JääskeläinenJE, RinneJ, LeinonenV, HiltunenM (2012) APOE4 predicts amyloid-beta in cortical brain biopsy but not idiopathic normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry83, 1119–1124.
GalaskoD, ChangL, MotterR, ClarkCM, KayeJ, KnopmanD, ThomasR, KholodenkoD, SchenkD, LieberburgI, MillerB, GreenR, BasheradR, KertilesL, BossMA, SeubertP (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer’s disease and relation to apolipoprotein E genotype. Arch Neurol55, 937–945.
RosesAD (1996) Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med47, 387–400.
33.
RinneJO, WongDF, WolkDA, LeinonenV, ArnoldSE, BuckleyC, SmithA, McLainR, SherwinPF, FarrarG, KailajärviM, GrachevID (2012) [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: Pooled analysis of four studies. Acta Neuropathol124, 833–845.
34.
LeinonenV, KoivistoAM, SavolainenS, RummukainenJ, TamminenJN, TillgrenT, VainikkaS, PyykköOT, MölsäJ, FraunbergM, PirttiläT, JääskeläinenJE, SoininenH, RinneJ, AafuzoffI (2010) Amyloid and tau proteins in cortical brain biopsy and Alzheimer’s disease. Ann Neurol446–453.
35.
MagdalinouNK, LingH, SmithJD, SchottJM, WatkinsLD, LeesAJ (2013) Normal pressure hydrocephalus or progressive supranuclear palsy? A clinicopathological case series. J Neurol260, 1009–1013.
36.
JingamiN, Asada-UtsugiM, UemuraK, NotoR, TakahashiM, OzakiA, KiharaT, KageyamaT, TakahashiR, ShimohamaS, KinoshitaA (2015) Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer’s disease. J Alzheimers Dis45, 109–115.
37.
KoivistoAM, KurkiMI, AlafuzoffI, SutelaA, RummukainenJ, SavolainenS, VanninenR, JääskeläinenJE, SoininenH, LeinonenV (2016) High risk of dementia in ventricular enlargement with normal pressure hydrocephalus related symptoms. J Alzheimers Dis52, 497–507.
38.
MalmJ, Graff-RadfordNR, IshikawaM, KristensenB, LeinonenV, MoriE, OwlerBK, TullbergM, WilliamsMA, RelkinNR (2013) Influence of comorbidities in idiopathic normal pressure hydrocephalus – research and clinical care. A report of the ISHCSF task force on comorbidities in iNPH. Fluids Barriers CNS10, 2281181022.
39.
OginoA, KazuiH, MiyoshiN, HashimotoM, OhkawaS, TokunagaH, IkejiriY, TakedaM (2006) Cognitive impairment in patients with idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Disord21, 113–119.
40.
KitagakiH, MoriE, IshiiK, YamajiS, HironoN, ImamuraT (1998) CSF spaces in idiopathic normal pressure hydrocephalus: Morphology and volumetry. Am J Neuroradiol19, 1277–1284.
41.
IshiiK, KandaT, HaradaA, MiyamotoN, KawaguchiT, ShimadaK, OhkawaS, UemuraT, YoshikawaT, MoriE (2008) Clinical impact of the callosal angle in the diagnosis of idiopathic normal pressure hydrocephalus. Eur Radiol18, 2678–2683.
42.
YamashitaF, SasakiM, TakahashiS, MatsudaH, KudoK, NarumiS, TerayamaY, AsadaT (2010) Detection of changes in cerebrospinal fluid space in idiopathic normal pressure hydrocephalus using voxel-based morphometry. Neuroradiology52, 381–386.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
45.
BuG (2009) Apolipoprotein E and its receptors in Alzheimer’s disease: Pathways, pathogenesis and therapy. Nat Rev Neurosci10, 333–344.
46.
HuangY, MuckeL (2012) Alzheimer mechanisms and therapeutic strategies. Cell148, 1204–1222.
